Examples of using The concomitant administration in English and their translations into Finnish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
The concomitant administration of CRESEMBA and efavirenz is contraindicated.
Caution should be used when administering Rapiscan to patients with a history of seizures orother risk factors for seizures, including the concomitant administration of medicinal products that lower seizure threshold e.g. antipsychotics, antidepressants, theophyllines, tramadol, systemic steroids and quinolones.
The concomitant administration of CRESEMBA and ketoconazole is contraindicated.
As this may be a class-effect, the concomitant administration of Xadago and pethidine is contraindicated see section 4.3.
The concomitant administration with alfuzosin is contraindicated see section 4.5.
Clopidogrel: In a phase I study in young healthy male volunteers, the concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy.
The concomitant administration with APTIVUS, co-administered with low dose ritonavir, is not recommended.
In view of the MAO inhibitory activity of safinamide, the concomitant administration of Xadago and dextromethorphan is not recommended, or if concomitant treatment is necessary, it should be used with caution see section 4.4.
The concomitant administration of Gardasil with vaccines other than the ones above has not been studied.
Therefore, the concomitant administration of Kaletra with PIs requires close monitoring.
The concomitant administration with fusidic acid is contraindicated in dermatological infections see section 4.5.
In clinical trials, the concomitant administration of Rapamune and HMG-CoA reductase inhibitors and/ or fibrates was well tolerated.
The concomitant administration of CRESEMBA and high doses of ritonavir(> 200 mg every 12 hours) is contraindicated.
In rare cases, the concomitant administration of sirolimus and ACE inhibitors has resulted in angioneurotic oedema-type reactions.
The concomitant administration of Gardasil with vaccines other than hepatitis B(recombinant) vaccine has not been studied.
In a study conducted in healthy volunteers, the concomitant administration of repaglinide(a single dose of 0.25 mg) and ciclosporin(repeated dose at 100 mg) increased repaglinide AUC and Cmax about 2.5-fold and 1.8-fold respectively.
The concomitant administration of medicinal products associated with bleeding risk should be undertaken with caution see section 4.4.
The concomitant administration of sirolimus and angiotensin-converting enzyme inhibitors has resulted in angioneurotic oedema-type reactions.
The concomitant administration of Rilonacept Regeneron with other IL-1 inhibitors has not been studied and is therefore not recommended.
The concomitant administration of Ceplene and IL-2 therefore aims to optimise the anti-leukaemic functions of NK cells and T cells.
The concomitant administration of CRESEMBA and carbamazepine, phenytoin and long-acting barbiturates such as phenobarbital is contraindicated.
The concomitant administration of probenicid can produce higher and sustained concentrations of cefuroxime in the serum and in the bile.
The concomitant administration of the vaccine with any immunoglobulin including Vaccinia Immune Globulin(VIG) has not been studied and should be avoided.
The concomitant administration of ketoconazole should be avoided, unless the benefits outweigh the potentially increased risk of systemic effects of salmeterol treatment.
If the concomitant administration of an H2-receptor antagonist is medically necessary, pazopanib should be taken without food at least 2 hours before or at least 10 hours after a dose of an H2-receptor antagonist.
The concomitant administration of salicylates and valproic acid may result in decreased valproic acid protein binding and inhibition of valproic acid metabolism resulting in increased serum levels of total and free valproic acid.
The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments(such as ß-blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia see section 4.5.
The concomitant administration of the product with other anti-hypertensive agents(e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may potentially lead to additive hypotensive effects.
The concomitant administration of Rilonacept Regeneron with any TNF inhibitor is not recommended(see section 4.4), because an increased incidence of serious infections has been associated with administration of another IL-1 blocker in combination with TNF inhibitors.
The concomitant administration of this veterinary medicinal product with other potassium-sparing treatments(such as ß-blockers, calcium channels blockers, angiotensin receptor blockers) may potentially lead to hyperkalaemia see section"Special precautions for use in animals.